AGN CEO on Ifenprodil phase 2b study Algernon Pharmaceuticals' (AGN.c AGNPF) CEO on AGN's Phase 2b Ifenprodi-Chronic Cough study.
The 180-patient, 3-month study is planned to start in Q3.
AGN's Phase 2a study showed that Ifenprodil reduced patient cough counts so AGN is optimistic about what Phase 2b will yield.